NCT06690281 2025-09-11
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
Clinical Trials
24 trialsNCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
NCT05240040 2024-11-20
Treat Primary and Metastatic Liver Tumors
Methodist Health System
Withdrawn
NCT06284226 2024-04-16
CCT-ANK-11
Beijing Kejing Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Withdrawn
NCT05292443 2024-02-23
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer
Geneplus-Beijing Co. Ltd.
Withdrawn
NCT05514912 2023-12-26
Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial
Emory University
Phase 2 Withdrawn
NCT05510427 2023-08-15
Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT02174575 2023-05-03
Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery
Tokyo Medical and Dental University
Phase 4 Withdrawn
NCT03999658 2023-05-01
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
Sorrento Therapeutics, Inc.
Phase 2 Withdrawn
NCT04895046 2022-06-29
Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT04546828 2022-06-15
A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea
Samsung Medical Center
Phase 2 Withdrawn
NCT04480190 2022-04-20
Neoadjuvant Therapy in Biliary Adenocarcinoma
University of Cincinnati
Phase 1 Withdrawn
NCT04511793 2021-07-19
Hepatic Artery Infusion (HAI) Program at Duke University
Duke University
Phase NA Withdrawn
NCT04479904 2021-06-22
A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Withdrawn
NCT03563352 2020-12-14
Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer
University of Southern California
Withdrawn
NCT03801499 2020-05-21
Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
Phase 2 Withdrawn
NCT02106871 2017-10-27
PCC
The University of Texas Medical Branch, Galveston
Phase 1 Withdrawn
NCT00386516 2017-08-01
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
Galectin Therapeutics Inc.
Phase 2 Withdrawn
NCT00604266 2017-05-04
PET/MRCP
University of Toronto
Withdrawn
NCT03117855 2017-04-18
Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery
City of Hope Medical Center
Phase 1 Withdrawn
NCT01875549 2016-04-26
Comparison Between Unilateral Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction to Use a LCD Stent
Samsung Medical Center
Phase NA Withdrawn
NCT01501604 2015-09-17
BKM120 in Cancers With PIK3CA Activating Mutations
Massachusetts General Hospital
Phase 2 Withdrawn
NCT01775280 2015-06-09
RESRAD
University of Zurich
Phase 2 Withdrawn
NCT00713687 2012-08-10
GemOx-PDT
Technical University of Munich
Phase 2 Withdrawn